We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Intuitive Surgical Inc designs, manufactures and markets the da Vinci surgical system and related instruments and accessories, which is an advanced robot-assisted surgical system. The surgical system comprises a surgeon's console, patient-side cart, 3-D vision system, da Vinci Skills Simulator and Firefly Fluorescence Imaging. Intuitive Surgical's robot-based da Vinci surgical system enables minimally-invasive surgery that reduces the trauma associated with open surgery. The company also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures.'Additionally, the company sells various accessories comprising sterile drapes and vision products and other items that facilitate use of the da Vinci Surgical System, as well as Ion endoluminal system for biopsies. The company operates through three segments: Instruments and Accessories, Systems and Services.
- Recent ISRG Stock Price: $250.55
- Yearly Gain for ISRG stock: -7.81%
- Market Cap for ISRG stock: $90.46B
- P/E Ratio for ISRG stock: 67.764
Will ISRG's stock price go up? Is there an accurate ISRG stock forecast available?
TipRanks.com reports that Intuitive Surgical currently has 15 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $277.40. The target pricing ranges from a high ISRG forecast of $320.00 down to a low forecast of $215.00. Intuitive Surgical (ISRG)’s last closing stock price was $250.55 which would put the average price target at 10.72% upside.
In addition, TradingView issued a Neutral rating for ISRG stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ISRG stock.
Other analysts covering ISRG include:
- Richard Newitter of Truist Financial issued a Buy rating with the price target of $ 300 on 1 day ago
- Larry Biegelsen of Wells Fargo issued a Buy rating with the price target of $ 289 on 1 day ago
- Joanne Wuensch of Citigroup issued a Buy rating with the price target of $ 305 on 1 day ago
- Rick Wise of Stifel Nicolaus issued a Buy rating with the price target of $ 285 on 1 day ago
If you are wondering if ISRG is a good stock to buy, here are 3rd party ratings for ISRG stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 37% (92 out of 250)
What is the sentiment on the street regarding Intuitive Surgical? (Current ratings compiled by TipRanks.com)
- News Sentiment for ISRG stock: Neutral
- Blogger Consensus for ISRG stock: Bullish
- Media Buzz for ISRG stock: Very High
- Insider Signal for ISRG stock: n/a
- Investor Sentiment for ISRG stock: Very Negative
- Hedge Fund signal for ISRG stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on ISRG stock including scouring the social networks like ISRG StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ISRG stock chart >>
Summary: Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.
- Recent ABT Stock Price: $111.07
- Yearly Gain for ABT stock: -5.91%
- Market Cap for ABT stock: $198.78B
- P/E Ratio for ABT stock: 28.381
Will ABT's stock price go up? Is there an accurate ABT stock forecast available?
TipRanks.com reports that Abbott Labs currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $123.55. The target pricing ranges from a high ABT forecast of $133.00 down to a low forecast of $107.00. Abbott Labs (ABT)’s last closing stock price was $111.07 which would put the average price target at 11.24% upside.
In addition, TradingView issued a Buy rating for ABT stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ABT stock.
Other analysts covering ABT include:
- Rick Wise of Stifel Nicolaus issued a Buy rating with the price target of $ 125 on 21 hours ago
- Lee Hambright of Bernstein issued a Buy rating with the price target of $ 132 on 21 hours ago
- Marie Thibault of BTIG issued a Buy rating with the price target of $ 125 on 1 day ago
- Michael Polark of Wolfe Research issued a Sell rating with the price target of $ 107 on 1 day ago
If you are wondering if ABT is a good stock to buy, here are 3rd party ratings for ABT stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 42% (104 out of 250)
What is the sentiment on the street regarding Abbott Labs? (Current ratings compiled by TipRanks.com)
- News Sentiment for ABT stock: Neutral
- Blogger Consensus for ABT stock: Bullish
- Media Buzz for ABT stock: Very High
- Insider Signal for ABT stock: n/a
- Investor Sentiment for ABT stock: Very Negative
- Hedge Fund signal for ABT stock: Negative
The stock market is extremely volatile, and you need to do your own research on ABT stock including scouring the social networks like ABT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ABT stock chart >>
Summary: Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. The company's segmental details are provided below: Life Sciences segment offers a broad range of research tools used to analyze a range of critical areas including genes, proteins, metabolites and cells to understand the causes of diseases, identify new therapies, and test new drugs and vaccines. Range of industries served includes biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial. Diagnostics segment offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps to diagnose diseases and take suitable treatment decisions. Environmental & Applied Solutions segment offers products and services that help keep food and water supplies safe globally.
- Recent DHR Stock Price: $265.86
- Yearly Gain for DHR stock: -1.06%
- Market Cap for DHR stock: $201.65B
- P/E Ratio for DHR stock: 27.232
Will DHR's stock price go up? Is there an accurate DHR stock forecast available?
TipRanks.com reports that Danaher currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $300.27. The target pricing ranges from a high DHR forecast of $325.00 down to a low forecast of $270.00. Danaher (DHR)’s last closing stock price was $265.86 which would put the average price target at 12.94% upside.
In addition, TradingView issued a Sell rating for DHR stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on DHR stock.
Other analysts covering DHR include:
- Tycho Peterson of J.P. Morgan issued a Buy rating with the price target of $ 325 on 1 day ago
- Daniel Brennan of Cowen & Co. issued a Buy rating with the price target of $ 320 on 1 day ago
- Daniel Arias of Stifel Nicolaus issued a Hold rating with the price target of $ 270 on 1 day ago
- Vijay Kumar of Evercore ISI issued a Buy rating with the price target of $ 285 on 2 days ago
If you are wondering if DHR is a good stock to buy, here are 3rd party ratings for DHR stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Bottom 29% (177 out of 250)
What is the sentiment on the street regarding Danaher? (Current ratings compiled by TipRanks.com)
- News Sentiment for DHR stock: Very Bullish
- Blogger Consensus for DHR stock: Bullish
- Media Buzz for DHR stock: High
- Insider Signal for DHR stock: Negative
- Investor Sentiment for DHR stock: Very Negative
- Hedge Fund signal for DHR stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on DHR stock including scouring the social networks like DHR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for DHR stock chart >>
Summary: Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.
- Recent ICPT Stock Price: $18.37
- Yearly Gain for ICPT stock: 19.68%
- Market Cap for ICPT stock: $658.95M
- P/E Ratio for ICPT stock: 3.233
Will ICPT's stock price go up? Is there an accurate ICPT stock forecast available?
TipRanks.com reports that Intercept Pharma currently has 10 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $26.13. The target pricing ranges from a high ICPT forecast of $49.00 down to a low forecast of $14.00. Intercept Pharma (ICPT)’s last closing stock price was $18.37 which would put the average price target at 42.24% upside.
In addition, TradingView issued a Buy rating for ICPT stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ICPT stock.
Other analysts covering ICPT include:
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $ 28 on 1 day ago
- Navin Jacob of UBS issued a Hold rating with the price target of $ 20 on 3 days ago
If you are wondering if ICPT is a good stock to buy, here are 3rd party ratings for ICPT stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 35% (88 out of 250)
What is the sentiment on the street regarding Intercept Pharma? (Current ratings compiled by TipRanks.com)
- News Sentiment for ICPT stock: Very Bullish
- Blogger Consensus for ICPT stock: Neutral
- Media Buzz for ICPT stock: High
- Insider Signal for ICPT stock: n/a
- Investor Sentiment for ICPT stock: Very Positive
- Hedge Fund signal for ICPT stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on ICPT stock including scouring the social networks like ICPT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ICPT stock chart >>
Summary: Roche Holding AG Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology, metabolism and neuroscience. It has more than 60 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. Diagnostics division includes five business areas: Applied Science, Molecular Diagnostics, Professional Diagnostics, Tissue Diagnosis and Diabetes Care.
- Recent RHHVF Stock Price: $312.5
- Yearly Gain for RHHVF stock: -13.70%
- Market Cap for RHHVF stock: $262.69B
- P/E Ratio for RHHVF stock: 16.819
Will RHHVF's stock price go up? Is there an accurate RHHVF stock forecast available?
TipRanks.com reports that Roche Holding AG currently has 12 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $371.78. The target pricing ranges from a high RHHVF forecast of $436.11 down to a low forecast of $288.92. Roche Holding AG (RHHVF)’s last closing stock price was $312.5 which would put the average price target at 18.97% upside.
In addition, TradingView issued a Sell rating for RHHVF stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on RHHVF stock.
Other analysts covering RHHVF include:
- Keyur Parekh of Goldman Sachs issued a Buy rating with the price target of $ 436.11 on 3 days ago
- Andrew Baum of Citigroup issued a Buy rating with the price target of $ 381.59 on 6 days ago
- Michael Leuchten of UBS issued a Hold rating with the price target of $ 343.43 on 6 days ago
- Richard Vosser of J.P. Morgan issued a Sell rating with the price target of $ 299.82 on 1 week ago
If you are wondering if RHHVF is a good stock to buy, here are 3rd party ratings for RHHVF stock:
- TipRanks.com: Hold
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: n/a
What is the sentiment on the street regarding Roche Holding AG? (Current ratings compiled by TipRanks.com)
- News Sentiment for RHHVF stock: Very Bullish
- Blogger Consensus for RHHVF stock: Bullish
- Media Buzz for RHHVF stock: Medium
- Insider Signal for RHHVF stock: n/a
- Investor Sentiment for RHHVF stock: Very Positive
- Hedge Fund signal for RHHVF stock: No Signal
The stock market is extremely volatile, and you need to do your own research on RHHVF stock including scouring the social networks like RHHVF StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RHHVF stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================